^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR G719D

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    High-confidence AI-based biomarker profiling for H&E slides to optimize pathology workflow in lung cancer. (ASCO 2023)
    Image-based molecular detection can serve as an accurate and fast detection method to be used in the clinical setting for monitoring and prioritizing current pathology workflow. Specifically, it can detect a major fraction of the non-targetable patients and optimize their diagnostic flow.
    IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR L858R • ROS1 fusion • EGFR negative • ALK-ROS1 fusion • EGFR G719D
    |
    Idylla™ EGFR Mutation Test
    2years
    A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation (AACR 2022)
    Binimetinib plus erlotinib demonstrated a manageable safety profile and modest efficacy including one objective response in a patient with KRAS mutation. With novel small molecule inhibitors of RAS and selective EGFR and other MAPK pathway inhibitors in development, these results support that such combination targeted approaches may hold clinical utility.
    P1 data • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • KRAS G12D • KRAS G12 • EGFR G719D
    |
    erlotinib • Mektovi (binimetinib)